<DOC>
	<DOCNO>NCT02932566</DOCNO>
	<brief_summary>This randomise , double-blind , placebo-controlled , phase 2 study aim evaluate efficacy safety anti-fibrotic drug pirfenidone treatment patient heart failure preserve leave ventricular ejection fraction ( HFpEF ) . Participants randomise receive either pirfenidone placebo , period 12 month .</brief_summary>
	<brief_title>The Efficacy Safety Pirfenidone Patients With Heart Failure Preserved Left Ventricular Ejection Fraction</brief_title>
	<detailed_description>Myocardial fibrosis key pathological mechanism HFpEF . Pirfenidone anti-fibrotic medication license treatment idiopathic lung fibrosis , reduces lung function decline , improve progression free survival reduces cause mortality . In pre-clinical model , pirfenidone attenuate profibrotic pathway associate regression myocardial fibrosis . Previous study HFpEF population use anti-fibrotic medication , angiotensin-converting enzyme ( ACE ) inhibitor , angiotensin-II receptor blocker aldosterone antagonist show benefit reach secondary end-points reduce mortality . HFpEF final result number specific underlying pathological mechanism , target treatment mechanism cite future approach clinical trial . The investigator aim select population HFpEF patient high level interstitial myocardial fibrosis measure cardiac MRI ( CMR ) , randomise participant receive pirfenidone placebo . The primary outcome detect significant reduction myocardial fibrosis measure CMR 12 month intervention .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>1 . Written informed consent . 2 . Male female ; age 40 year old . 3 . HF , define one symptom present time screening , one sign present time screen previous 12 month . Symptoms sign define : Symptoms : dyspnoea exertion , orthopnoea paroxysmal nocturnal dyspnoea Signs : peripheral oedema , crackle chest auscultation postcough , raise jugular venous pressure chest xray demonstrate pleural effusion , pulmonary congestion , cardiomegaly 4 . Left Ventricular Ejection Fraction ( LVEF ) &gt; 45 % Visit 0 , ( local LVEF measurement make use echocardiography CMR ) . 5 . BNP ≥ 100 pg/ml NTproBNP ≥ 300 pg/ml record Visit 0 . For patient atrial fibrillation Visit 0 ECG , BNP &gt; 300pg/ml NTproBNP &gt; 900 pg/ml Visit 0 . 6 . Myocardial fibrosis , define Extracellular Matrix ( ECM ) volume &gt; 27 % CMR Visit 0 . 1 . Myocardial infarction , coronary artery bypass graft surgery percutaneous coronary intervention within previous 6 month . 2 . Probable alternative cause patient 's HF symptom opinion investigator primarily account patient 's dyspnoea significant pulmonary disease , anaemia obesity . Specifically , patient exclude : 1 . Severe chronic obstructive pulmonary disease ( COPD ) ( i.e. , require home oxygen , chronic nebuliser therapy , chronic oral steroid therapy ) , 2 . Haemoglobin &lt; 9 g/dl , 3 . Body mass index ( BMI ) &gt; 55 kg/m2 . 3 . Known pericardial constriction , genetic hypertrophic cardiomyopathy , infiltrative cardiomyopathy . 4 . Clinically significant congenital heart disease . 5 . Presence severe valvular heart disease . 6 . Atrial fibrillation flutter rest ventricular rate &gt; 100 bpm . 7 . Any medical condition , opinion Investigator , may place patient high risk his/her participation study , likely prevent patient comply requirement study complete study . 8 . Severe renal dysfunction Visit 0 , define estimate Glomerular Filtration Rate ( eGFR ) &lt; 30 mL/min ( use Chronic Kidney Disease Epidemiology Collaboration Equation ( CKDEPI ) calculation ) , endstage renal disease require dialysis . 9 . History severe hepatic impairment liver dysfunction Visit 0 , define total bilirubin upper limit normal ( ULN ) ( exclude patient Gilbert 's syndrome ) , aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &gt; 3 time ULN alkaline phosphatase &gt; 2.5 time ULN . 10 . Prolonged correct QT interval , define correct QT interval &gt; 500 msec ECG use Bazett formula . 11 . Known hypersensitivity component investigational medicinal product ( IMP ) . 12 . Use investigational drug time enrolment , within 30 day 5 halflives enrolment , whichever longer . 13 . Fluvoxamine use within 28 day Visit 0 . 14 . Contraindication MRI scanning gadoliniumbased contrast agent 15 . Pregnancy , lactation planning pregnancy . Women childbearing capacity require negative serum pregnancy test treatment , must agree pregnancy test study visit define Section 7.2.5 must agree maintain highly effective contraception study 3 month thereafter . Similarly male participant female partner childbearing potential must agree maintain highly effective contraception study 3 month thereafter .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Heart failure preserve ejection fraction ( HFpEF )</keyword>
	<keyword>Myocardial fibrosis</keyword>
	<keyword>Extracellular volume fraction ( ECV )</keyword>
	<keyword>Interstitial fibrosis</keyword>
</DOC>